English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/201623
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Hepatitis C virus and cumulative infections are associated with atherogenic cardiovascular events in HIV-infected subjects

AuthorsGenebat, Miguel; Tarancón-Díez, Laura; Pulido, Ildefonso; Álvarez-Ríos, A. I.; Muñoz-Fernandez, M. Angeles; Ruiz-Mateos, Ezequiel; Leal, Manuel CSIC
KeywordsInfection
Atherosclerosis
Hepatitis C
HIV
Issue DateSep-2019
PublisherElsevier
CitationAntiviral Research 169: 104527 (2019)
Abstract[Objectives] to analyze the association between HCV coinfection and cumulative infections with the development of a cardiovascular disease in HIV-infected subjects.
[Methods] HIV-infected subjects attended at Virgen del Rocio University Hospital, between January 1982 and March 2018, were considered if fulfilled the following criteria: at least two visits to the HIV clinic, clinical records with data about VZV reactivation and bacterial infections, available data on HCV coinfection status. Atherogenic cardiovascular events were registered. To analyze factors associated with the development of cardiovascular event, a logistic regression analysis was performed.
[Results] 823 subjects were included in the study. During the observational period, 58/823 (7.05%) developed a cardiovascular event. Advanced age at HIV-1 diagnosis, a low T-CD4 nadir, HCV coinfection and the burden of infections were independently associated with the risk of developing a cardiovascular event, apart from lipid levels and diabetes.
[Conclusions] both HCV and the burden of infections are associated with an increased risk of cardivascular event in HIV-infected patients, together with other cardiovascular risk factors. Therapeutic strategies such as HCV erradication or VZV immunization could ameliorate cardiovascular risk in these subjects.
Publisher version (URL)https://doi.org/10.1016/j.antiviral.2019.05.016
URIhttp://hdl.handle.net/10261/201623
DOIhttp://dx.doi.org/10.1016/j.antiviral.2019.05.016
ISSN0166-3542
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf59,24 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.